The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: a bi-centric retrospective cohort study of 244 cases - Summary - MDSpire
Advertisement
The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: a bi-centric retrospective cohort study of 244 cases
To examine the prognostic potential of Ki67 on the rate of pathological complete response (pCR) and invasive disease-free survival (IDFS) in early HER2-positive breast cancer and to test specific suggested Ki67 cut-offs.
Key Findings:
Ki67 showed no significant association with pCR or IDFS in the studied cohort, suggesting it may not be a reliable biomarker.
The previously suggested Ki67 cut-offs did not demonstrate predictive value for treatment outcomes, indicating a need for alternative biomarkers.
More reliable predictive factors should guide therapeutic decisions in HER2-positive breast cancer.
Interpretation:
The findings indicate that Ki67 is not a reliable biomarker for predicting treatment response or survival outcomes in early HER2-positive breast cancer, challenging its use in clinical decision-making and highlighting the need for alternative biomarkers.
Limitations:
Retrospective design may introduce bias.
Data derived from only two centers may limit generalizability.
Potential confounding factors not fully accounted for despite statistical adjustments.
Retrospective data collection may impact data quality.
Conclusion:
Ki67 should not be used to guide therapeutic decisions in routine practice for HER2-positive breast cancer, emphasizing the need for more reliable predictive factors.
